Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes
Maha K. Rahim(University of California, San Francisco), Matthew H. Spitzer(Unknown), Candace C. Liu(Stanford University), Matthew F. Krummel(University of California, San Francisco), Alexander Cheung(University of California, San Francisco), Iliana Tenvooren(University of California, San Francisco), Bushra Samad(University of California, San Francisco), Vrinda Johri(University of California, San Francisco), Elizabeth McCarthy(University of California, San Francisco), Trine Line Hauge Okholm(University of California, San Francisco), Michael Angelo(Stanford University), William O’Gorman(Genomic Health (United States)), Alain P. Algazi(University of California, San Francisco), Patrick K. Ha(University of California, San Francisco), Katherine C. Wai(University of California, San Francisco), Lawrence Fong(UCSF Helen Diller Family Comprehensive Cancer Center), Jacqueline L. Yee(University of California, San Francisco), Alexis J. Combes(University of California, San Francisco), Diana M. Marquez(Stanford University), Kyle B. Jones(University of California, San Francisco), Stanley Tamaki(University of California, San Francisco), Brittany Davidson(University of California, San Francisco), Annemieke van Zante(University of California, San Francisco)
Cited by 410
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Systemic immunity in cancer
|Nature reviews. Cancer|2021|1.3k